CVRx Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
CVRx şirketinin kazançları yıllık ortalama -11.3% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 13.6% oranında artan oldu. Gelirler yıllık ortalama 34.2% oranında artan oldu.
Anahtar bilgiler
-11.28%
Kazanç büyüme oranı
77.00%
EPS büyüme oranı
| Medical Equipment Sektör Büyümesi | 8.90% |
| Gelir büyüme oranı | 34.18% |
| Özkaynak getirisi | -180.91% |
| Net Marj | -89.15% |
| Son Kazanç Güncellemesi | 31 Mar 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Analiz Makalesi • May 15
The CVRx, Inc. (NASDAQ:CVRX) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Shareholders in CVRx, Inc. ( NASDAQ:CVRX ) had a terrible week, as shares crashed 22% to US$5.74 in the week since its...
Anlatı Güncellemesi • May 05
CVRX: Reduced Multiple Expectations Will Likely Constrain Future Share Price Upside
Analysts have reduced their average CVRx price target by $1 to reflect updated views on the company’s risk profile, growth trajectory, profitability expectations, and likely P/E multiple, while keeping fair value broadly in line with prior estimates. Analyst Commentary Recent Street research on CVRx points to a more cautious tone, with the headline takeaways centered on slightly lower price targets and an increased focus on execution and valuation risks.Anlatı Güncellemesi • Apr 19
CVRX: Execution Risks And Updated Assumptions Will Likely Restrain Upside
Analysts have trimmed their price targets on CVRx by $1, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research notes, including one from JPMorgan, point to a more cautious stance on CVRx, reflected in the $1 price target trims.Anlatı Güncellemesi • Mar 31
CVRX: Execution Risks And Recent Price Cuts Will Likely Limit Upside
Analysts have trimmed their CVRx price targets by $1 to reflect updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations, while maintaining their fair value estimate at $6.00. Analyst Commentary Recent Street research, including updated work from JPMorgan, reflects a more cautious stance on CVRx even as the published fair value estimate remains at $6.00.Anlatı Güncellemesi • Mar 16
CVRX: Execution Risks Around Profitability Path Will Likely Cap Future Upside
Analysts have trimmed their CVRx price targets by $1 to $6, reflecting updated assumptions around revenue growth, discount rate, profit margins, and future P/E expectations. Analyst Commentary Recent research updates point to a more cautious stance on CVRx, with both JPMorgan and other bearish analysts trimming price targets by $1.Anlatı Güncellemesi • Mar 01
CVRX: Reimbursement Progress Will Face Cautious Outlook On Profitability Path
Analysts have trimmed their price target on CVRx by $1, reflecting updated assumptions around discount rates, revenue growth, profit margins and forward P/E that still align with recent Street research from firms that reduced their targets by a similar amount. Analyst Commentary Street research on CVRx has recently centered on slightly lower price targets, including a US$1 trim from JPMorgan, which aligns with similar reductions from other bearish analysts.Analiz Makalesi • Feb 15
Analysts Are Updating Their CVRx, Inc. (NASDAQ:CVRX) Estimates After Its Full-Year Results
One of the biggest stories of last week was how CVRx, Inc. ( NASDAQ:CVRX ) shares plunged 24% in the week since its...Anlatı Güncellemesi • Feb 15
CVRX: Reimbursement Shift And BENEFIT-HF Trial Will Reshape Long-Term Upside
Analysts have trimmed their CVRx price targets by $1, reflecting updated fair value estimates and assumptions on growth, profitability, and future P/E multiples, while maintaining a constructive view on the story. Analyst Commentary Recent Street research includes price target trims of $1 from both JPMorgan and other bearish analysts, which reflect a more cautious stance on CVRx's risk and reward profile.Analiz Makalesi • Dec 30
CVRx, Inc.'s (NASDAQ:CVRX) Popularity With Investors Under Threat As Stock Sinks 26%
CVRx, Inc. ( NASDAQ:CVRX ) shareholders won't be pleased to see that the share price has had a very rough month...Analiz Makalesi • Nov 08
CVRx, Inc. (NASDAQ:CVRX) Released Earnings Last Week And Analysts Lifted Their Price Target To US$11.50
CVRx, Inc. ( NASDAQ:CVRX ) just released its quarterly report and things are looking bullish. CVRx beat expectations...Analiz Makalesi • Oct 16
After Leaping 39% CVRx, Inc. (NASDAQ:CVRX) Shares Are Not Flying Under The Radar
CVRx, Inc. ( NASDAQ:CVRX ) shares have had a really impressive month, gaining 39% after a shaky period beforehand...Analiz Makalesi • Sep 16
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Aug 08
Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Second-Quarter Report
It's been a sad week for CVRx, Inc. ( NASDAQ:CVRX ), who've watched their investment drop 13% to US$6.94 in the week...Analiz Makalesi • Jul 15
CVRx, Inc.'s (NASDAQ:CVRX) P/S Is Still On The Mark Following 25% Share Price Bounce
CVRx, Inc. ( NASDAQ:CVRX ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Jul 02
CVRx: Sell-Off Ignores Its True Potential
Summary CVRx offers a unique, FDA-approved heart failure therapy with Medicare reimbursement, positioning it for significant market adoption and growth. The recent share price drop is an overreaction to sales force restructuring and reimbursement fears, while earnings and revenue estimates remain stable. Current valuation is deeply discounted versus sector peers, despite high-teens revenue growth and clear operating leverage potential as sales ramp up. Management insider buying and a net cash balance sheet reinforce my conviction that CVRX is a speculative Buy at these levels. Read the full article on Seeking AlphaAnaliz Makalesi • Jun 14
Is CVRx (NASDAQ:CVRX) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • May 09
Investors Appear Satisfied With CVRx, Inc.'s (NASDAQ:CVRX) Prospects As Shares Rocket 25%
Those holding CVRx, Inc. ( NASDAQ:CVRX ) shares would be relieved that the share price has rebounded 25% in the last...Seeking Alpha • Apr 09
CVRx, Inc.: Overreaction Creates Buying Opportunity
Summary CVRx, Inc. stock has recently dropped 40%, presenting a buying opportunity as the long-term growth potential remains intact. Barostim has strong clinical results and significant market potential, with a $2.2 billion TAM. Average selling prices can potentially improve as the market recognizes Barostim's effectiveness. CVRX shares are a buy with a price target of $10. Read the full article on Seeking Alpha
Yeni Anlatı • Mar 29
Expanding 48 US Territories And New Codes Will Broaden Access
Expansion in US territories and implanting centers is expected to drive significant revenue growth and market penetration.Analiz Makalesi • Mar 07
With A 29% Price Drop For CVRx, Inc. (NASDAQ:CVRX) You'll Still Get What You Pay For
CVRx, Inc. ( NASDAQ:CVRX ) shares have had a horrible month, losing 29% after a relatively good period beforehand...Analiz Makalesi • Jan 16
Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 27%
Despite an already strong run, CVRx, Inc. ( NASDAQ:CVRX ) shares have been powering on, with a gain of 27% in the last...Analiz Makalesi • Dec 26
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Nov 07
CVRx: Impressive Top-Line Growth Seems Priced In
Summary CVRx's Barostim therapy shows strong clinical success and impressive revenue growth. Recent reimbursement approvals from CMS enhance Barostim's sales potential. Despite double-digit sales growth and a promising product, CVRx's path to profitability is hindered by escalating SG&A costs and potential future shareholder dilution. CVRX is a hold with a price target of $14. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 01
Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report
The investors in CVRx, Inc. 's ( NASDAQ:CVRX ) will be rubbing their hands together with glee today, after the share...Analiz Makalesi • Oct 10
Investors Still Waiting For A Pull Back In CVRx, Inc. (NASDAQ:CVRX)
When you see that almost half of the companies in the Medical Equipment industry in the United States have...Analiz Makalesi • Jul 31
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • Jun 18
Why Investors Shouldn't Be Surprised By CVRx, Inc.'s (NASDAQ:CVRX) 32% Share Price Surge
Those holding CVRx, Inc. ( NASDAQ:CVRX ) shares would be relieved that the share price has rebounded 32% in the last...Analiz Makalesi • May 04
The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 47%
To the annoyance of some shareholders, CVRx, Inc. ( NASDAQ:CVRX ) shares are down a considerable 47% in the last month...Analiz Makalesi • Apr 10
Rock star Growth Puts CVRx (NASDAQ:CVRX) In A Position To Use Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Feb 29
The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 25%
CVRx, Inc. ( NASDAQ:CVRX ) shareholders won't be pleased to see that the share price has had a very rough month...Analiz Makalesi • Nov 11
Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 34%
CVRx, Inc. ( NASDAQ:CVRX ) shareholders are no doubt pleased to see that the share price has bounced 34% in the last...Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
CVRx nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Mar 26 | 59 | -53 | 89 | 12 |
| 31 Dec 25 | 57 | -53 | 88 | 11 |
| 30 Sep 25 | 56 | -52 | 87 | 11 |
| 30 Jun 25 | 55 | -52 | 86 | 10 |
| 31 Mar 25 | 53 | -52 | 84 | 11 |
| 31 Dec 24 | 51 | -60 | 91 | 11 |
| 30 Sep 24 | 47 | -58 | 88 | 11 |
| 30 Jun 24 | 44 | -54 | 82 | 11 |
| 31 Mar 24 | 42 | -52 | 77 | 11 |
| 31 Dec 23 | 39 | -41 | 65 | 12 |
| 30 Sep 23 | 35 | -43 | 62 | 12 |
| 30 Jun 23 | 31 | -43 | 59 | 12 |
| 31 Mar 23 | 26 | -43 | 55 | 11 |
| 31 Dec 22 | 22 | -41 | 50 | 10 |
| 30 Sep 22 | 19 | -41 | 46 | 9 |
| 30 Jun 22 | 16 | -38 | 41 | 8 |
| 31 Mar 22 | 14 | -44 | 34 | 8 |
| 31 Dec 21 | 13 | -43 | 28 | 8 |
| 30 Sep 21 | 11 | -36 | 21 | 6 |
| 30 Jun 21 | 9 | -33 | 16 | 6 |
| 31 Mar 21 | 7 | -19 | 12 | 6 |
| 31 Dec 20 | 6 | -14 | 10 | 6 |
| 31 Dec 19 | 6 | -15 | 6 | 9 |
Kaliteli Kazançlar: CVRX şu anda kârlı değil.
Büyüyen Kar Marjı: CVRX şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: CVRX kârlı değildir ve zararlar son 5 yılda yılda 11.3% oranında artmıştır.
Büyüme Hızlandırma: CVRX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: CVRX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 14.8% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: CVRX hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -180.91% ) sahiptir.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 08:23 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
CVRx, Inc. 9 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| William Plovanic | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Sarah James | Cantor Fitzgerald & Co. |